Incorporating the 40-gene expression profile (40-GEP) test for poorly differentiated cutaneous squamous cell carcinoma (cSCC) tumors mitigates risk assessment uncertainty from histologic grading. J of Skin [Internet]. 2023 Mar. 13 [cited 2025 Apr. 19];7(2):s164. Available from: https://skin.dermsquared.com/skin/article/view/2019